Literature DB >> 11093791

Synthetic modification of prostaglandin f(2alpha) indicates different structural determinants for binding to the prostaglandin F receptor versus the prostaglandin transporter.

V L Schuster1, S Itoh, S W Andrews, R M Burk, J Chen, K M Kedzie, D W Gil, D F Woodward.   

Abstract

Several principles governing the binding of E series prostaglandins to EP receptors have emerged in recent years. The C-1 carboxyl group binds electrostatically to a conserved arginine residue in the seventh transmembrane segment of the receptor. Prostaglandin E analogs involving bioisosteric replacements of the carboxyl group, such as acylsulfonamide, are also active. In addition, structurally similar esters may also exhibit similar affinity, presumably by virtue of hydrogen bonding. Other regions of the substrate molecule appear to bind to other domains of EP receptors, either via hydrophobic interactions or by hydrogen bonding. Less information is available about the structural requirements for substrate binding to FP receptors. Prostanoids also bind to the prostaglandin transporter PGT. In this case, a conserved C-1 carboxyl group is critically important, since C-1 esters exhibit little affinity. Here we examined the binding of chemically diverse PGF(2alpha) structural analogs to the FP receptor and compared these with binding by the PG transporter. PGT recognized a wide range of anionic substituents. In contrast, the carboxylic acid group was essential for optimal binding to the FP receptor, since replacement by larger moieties with a similar pK(a), such as acylsulfonamide and tetrazole, substantially decreased binding affinity. Interestingly, insertion of cyclic substituents in the omega chain increased binding to the FP receptor but reduced affinity for PGT, and substitution for the 15-hydroxyl group produced only a modest reduction in FP receptor binding, but eliminated binding by PGT. Because extracellular PGF(2alpha) may compete for binding between FP receptors and PGT, these findings have implications for designing PGF(2alpha) analogs for treating disease states.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11093791     DOI: 10.1124/mol.58.6.1511

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  4 in total

1.  Acylsulfonamide-Functionalized Zwitterionic Gold Nanoparticles for Enhanced Cellular Uptake at Tumor pH.

Authors:  Tsukasa Mizuhara; Krishnendu Saha; Daniel F Moyano; Chang Soo Kim; Bo Yan; Young-Kwan Kim; Vincent M Rotello
Journal:  Angew Chem Int Ed Engl       Date:  2015-04-14       Impact factor: 15.336

Review 2.  Roles of Organic Anion Transporting Polypeptide 2A1 (OATP2A1/SLCO2A1) in Regulating the Pathophysiological Actions of Prostaglandins.

Authors:  Takeo Nakanishi; Ikumi Tamai
Journal:  AAPS J       Date:  2017-12-04       Impact factor: 4.009

3.  Biasing the prostaglandin F2α receptor responses toward EGFR-dependent transactivation of MAPK.

Authors:  Eugénie Goupil; Veronica Wisehart; Etienne Khoury; Brandon Zimmerman; Sahar Jaffal; Terence E Hébert; Stéphane A Laporte
Journal:  Mol Endocrinol       Date:  2012-05-25

4.  Identification by site-directed mutagenesis of amino acids contributing to ligand-binding specificity or signal transduction properties of the human FP prostanoid receptor.

Authors:  Frank Neuschäfer-Rube; Eva Engemaier; Sina Koch; Ulrike Böer; Gerhard P Püschel
Journal:  Biochem J       Date:  2003-04-15       Impact factor: 3.857

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.